Opinion|Videos|January 19, 2024
Optimizing Multiple Myeloma Treatment: Quadruplet Therapy
Health care professionals delve into discussions on using quadruplets in multiple myeloma treatment, addressing challenges, and considerations for high-risk patients.
Advertisement
Episodes in this series
This is a video synopsis/summary of a Peer Exchange featuring Joshua Richter, MD; Rafat Abonour, MD; Faith Davies, MD; and Amrita Krishnan, MD.
Richter discusses the role of K-based quadruplets for myeloma patients, referencing studies such as the PERSEUS trial (NCT03710603). Abonour emphasizes considering carfilzomib as a stronger proteasome inhibitor for high-risk and younger patients. Krishnan offers a contrarian view based on PERSEUS data, questioning the necessity of Krd (carfilzomib, lenalidomide, dexamethasone)-based regimens for all high-risk patients. The discussion extends to consolidation and long-term maintenance strategies, with Abonour highlighting the importance of correctly identifying high-risk patients and expressing interest in data on consolidation in ultra high-risk cases. Richter raises the question of continuing K beyond 2 years in maintenance, considering patient preferences and minimal residual disease dynamics. The panel contemplates a future app for personalized maintenance decisions.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Advertisement
Related to this article
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
Advertisement
Advertisement
Trending on AJMC
1
Preparing Practices for the Next Era of Hepatitis B Care
2
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
3
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
4
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
5